• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23352 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brentuximab vedotin (cutaneous T-cell lymphoma) - Addendum to Commission G18-01]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brentuximab vedotin (advanced Hodgkin lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brentuximab Vedotin - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2013     Andalusian Health Technology Assessment Area (AETSA) [Breast cancer ablation with radiofrequency. Systematic review]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Bravo pH monitoring in gastroesophageal reflux]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 13: The use of insulin glargine and insulin detemir to control type 1 diabetes mellitus]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 12: Clinical strategies for smoking cessation]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 11: Positron Emission Tomography (PET) in the diagnosis, staging and restaging of patients with colorectal cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 10: Rituximab in the treatment of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL)]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 09: Statins for the prevention of cardiovascular events]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 08: Drug-eluting stents and bare-metal stents in the treatment of coronary artery disease]
2011     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Brain injury rehabilitation - a health technology assessment]
2008     Committee for New Health Technology Assessment (CNHTA) [BRAF V600E mutation]
2011     Committee for New Health Technology Assessment (CNHTA) [BRAF Gene, Mutation(Peptide Nucleic Acid Mediated Real-time PCR Clamping Method)]
2008     Committee for New Health Technology Assessment (CNHTA) [BRAF gene mutation analysis]
1999     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) [Brachytherapy and prostate cancer]
2023     Norwegian Institute of Public Health (NIPH) [Brace compression for treatment of pectus carinatum: a rapid health technology assessment]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin use in adults and children with urinary tract function disorders]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin in adult patients with overactive bladder]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin in adult patients with dystonia]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin for the treatment of headache]
2011     Andalusian Health Technology Assessment Area (AETSA) [Botulinum toxin A in the treatment of morbid obesity]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib (pretreated chronic myelogenous leukaemia) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V. Addendum]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2013     Haute Autorite de sante (HAS) [Bone substitutes]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Bone marrow stem cell therapy for orthopedic conditions]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Bone graft substitutes in traumatology]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Boceprevir - Benefit assessment according to 35a Social Code Book V (dossier assessment)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blood values: do older people benefit from regular determination of vitamin B12 and vitamin D levels in the blood?]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Blood test for the identification and location of different types of cancer]
2019     Andalusian Health Technology Assessment Area (AETSA) [Blood test for the early diagnosis of pancreatic cancer. CancerSEEK]
2012     The Swedish Council on Health Technology Assessment (SBU) [Blood test for early diagnosis of Alzheimer's disease]
2022     HTA South [Blood group matching with genotyping]
2005     Finnish Office for Health Care Technology Assessment (Finohta) [Blood glucose self-monitoring in diabetes management]
2016     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Blood conservation strategies in cardiac surgery: the thromboelastogram and rotational thromboelastometer for monitoring hemostasis in cardiac surgery]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (ALL, paediatric patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (ALL, MRD-positive patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (acute lymphoblastic leukaemia)- Assessment according to §35a (para. 1., sentence 10) Social Code Book V (expiry of the decision)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (acute lymphoblastic leukaemia, Ph-, CD19+, children aged 1 to 18 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2011     The Swedish Council on Health Technology Assessment (SBU) [Bleeding peptic ulcer]
2008     Haute Autorite de sante (HAS) [Bladder volume measurement with portable ultrasound device]
2009     Committee for New Health Technology Assessment (CNHTA) [Bladder tumor antigen test]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bisphosphonates: Evidence report for the S3 guideline on atraumatic femoral head necrosis in adults]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Bisphosphonates as treatment for breast cancer]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Birch bark extract (epidermolysis bullosa) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Bioresorbable peripheral stents]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Bioquell airborne disinfection system]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Bioprothesis Perceval S, sutureless aortic valve replacement]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Biomedical treatment and diet supplements for the treatment of the autism spectrum disorder]
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Biomarkers in Parkinson's Disease]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Biomarker-based tests to support the decision for or against adjuvant systemic chemotherapy in primary breast cancer - state of knowledge]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer - Addendum to Commission D14-01]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Biomarker-based tests for deciding for or against adjuvant systemic chemotherapy in primary breast cancer with involvement of 1-3 lymph nodes]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Biomarker-based tests for deciding for or against adjuvant systemic chemotherapy in premenopausal women with primary breast cancer without lymph node involvement]
2011     Haute Autorite de sante (HAS) [Biology of haemostasis disorders: thrombin time]
2011     Haute Autorite de sante (HAS) [Biology of haemostasis disorders: testing for the G1691A mutation of the factor V gene (Leiden FV) and the G20210A mutation of the factor II gene]
2011     Haute Autorite de sante (HAS) [Biology of haemostasis disorders: testing for antibodies to platelet factor 4 in a patient with heparin – induced thrombocytopenia]
2011     Haute Autorite de sante (HAS) [Biology of haemostasis disorders: photometric platelet aggregation test]
2011     Haute Autorite de sante (HAS) [Biology of haemostasis disorders: lupus anticoagulant detection]
2011     Haute Autorite de sante (HAS) [Biology of haemostasis disorders: detection and titration of antihaemophilic factor (AHF) inhibitor]
2011     Haute Autorite de sante (HAS) [Biology of haemostasis disorders: bleeding time]
2011     Haute Autorite de sante (HAS) [Biology of haemostasis abnormalities – summary]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Biologics in patients with spondyloarthritis]
2010     Norwegian Knowledge Centre for the Health Services (NOKC) [Biologics for early rheumatoid arhritis]
2006     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Biologicals in patients with spondylitis ankylopoetica; the (REMICADE) therapy]
2005     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Biologicals in patients with psoriasis, infliximab (REMICADE) therapy]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Biological tissue adhesive versus standard suture in conjuctival autograft for the surgical treatment of pterygium]
2011     Andalusian Health Technology Assessment Area (AETSA) [Biological therapies in the treatment of rheumatoid arthritis]
2013     Andalusian Health Technology Assessment Area (AETSA) [Biological therapies in the treatment of ankylosing spondylitis: a comparison of efficacy and safety between different biological inhibitors of tumour necrosis factor-alpha]
2013     Andalusian Health Technology Assessment Area (AETSA) [Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Biological agents and tofacitinib in rheumatoid arthritis]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Biologic medications as second-line therapy for rheumatoid arthritis]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Biologic agents for the treatment of psoriasis]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Bioimpedance vector analysis in the assessment of nutritional status and body fluid volume in patients with chronic renal failure]
2011     Finnish Office for Health Care Technology Assessment (Finohta) [Bioimpedance in the estimation of dry weight in hemodialysis patients]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Biofeedback in adults with urinary and/or fecal incontinence]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Biofeedback in adults with fecal and/or urinary incontinence]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Biofeedback for women with urinary, fecal or combined incontinence]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenoses]
2024     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Biodegradable stents for the treatment of benign esophageal strictures. Monitoring study]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Bioabsorbable everolimus-eluting coronary stent (BVS) for treatment of coronary artery disease]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib (melanoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib (melanoma) - Addendum to Commission A18-62]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (psoriatic arthritis) – Addendum to Commission A23-60]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (plaque psoriasis) - Addendum to Commission A21-110]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Bilateral cochlear implants in hearing loss]
2007     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Bilateral cochlear implants in children: effectiveness, safety and cost. Situation in the Spanish regions]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bictegravir/emtricitabine/tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bictegravir/emtricitabine/tenofovir alafenamide (HIV infection) - Addendum to Commission A18-43]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bictegravir/ emtricitabine/ tenofovir alafenamide (HIV infections in children and adolescents) - Benefit assessment according to § 35a SGB V]